Peptide Bioavailability Explained

The short version

Bioavailability (abbreviated F, from "fraction") is the proportion of a drug dose that reaches the systemic circulation unchanged and is available to act on its target. By definition, an intravenous dose has 100% bioavailability because it enters the bloodstream directly. Every other route of administration introduces barriers that reduce F.

For peptides, the oral route is the problem: the gastrointestinal tract is highly effective at breaking peptides down into constituent amino acids. A swallowed insulin tablet would be digested before it reached the blood. This is why nearly every peptide therapeutic on the market is injected. It is also why oral semaglutide (Rybelsus), which achieves meaningful absorption by coupling the peptide to a specialized absorption enhancer, is considered an unusual technical achievement.

Defining bioavailability

Bioavailability is measured by comparing the area under the plasma concentration-time curve (AUC) after non-intravenous dosing to the AUC after an equivalent intravenous dose.^[7]If AUC after subcutaneous injection is 89% of the AUC after IV administration of the same dose, F = 0.89, or 89%.

Absolute bioavailability requires a reference IV dose for comparison. Relative bioavailability compares two non-IV routes to each other (for example, intramuscular versus subcutaneous) and is used when IV administration is not practical.

Two factors reduce bioavailability after non-IV administration:

• Incomplete absorption: Not all of the dose reaches the bloodstream because barriers at the absorption site prevent entry.
• First-pass metabolism: Drug absorbed from the gut passes through the liver before reaching the systemic circulation. Hepatic enzymes can metabolize a substantial fraction before it ever reaches its target. Peptides absorbed orally are also exposed to gut-wall enzymes before they even reach the portal blood.

Why peptides have low oral bioavailability

Three barriers work in series to prevent most peptides from being absorbed orally:^[1]

1. Gastric acid and pepsin

The stomach is an acidic environment (pH 1-3 when fasted) that denatures proteins and activates pepsin, an endopeptidase that begins cleaving peptide bonds in the stomach itself. Most peptides are substantially degraded before they leave the stomach. Enteric coatings can delay exposure to gastric contents, but they introduce their own challenges around timing and consistency of dissolution.

2. Intestinal proteases

The small intestine is the primary site of protein digestion. Pancreatic enzymes (trypsin, chymotrypsin, elastase, carboxypeptidases) and brush-border peptidases (aminopeptidase N, dipeptidyl peptidase IV) work together to reduce peptides to single amino acids and dipeptides, which are then absorbed as nutrients. A therapeutic peptide at pharmacological concentrations is a small substrate among a large pool of dietary protein; the digestive machinery degrades it with essentially the same efficiency.

3. The intestinal epithelial barrier

Even if a peptide survives proteolysis, it must cross the single layer of epithelial cells lining the intestine to reach the portal blood. Peptides are generally too large and too hydrophilic to pass through cells passively (transcellular route), and tight junctions between cells (paracellular route) restrict passage to very small molecules.^[6]The result is that typical peptides show oral bioavailability below 1-2%, and often much lower.

Bioavailability by route of administration

The route of administration is chosen to achieve adequate systemic exposure while minimizing inconvenience and risk. For peptides, the options and their typical bioavailability ranges are:

Values are representative ranges, not precise specifications for any single compound.^{[1],[6],[7],[8]}

Strategies that improve oral bioavailability

Several strategies attempt to overcome the barriers to oral peptide absorption, with varying degrees of success:

Absorption enhancers

Absorption enhancers are excipients that transiently increase the permeability of the intestinal epithelium or protect the peptide from enzymatic degradation long enough for it to be absorbed. Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) is the most clinically validated example. SNAC works primarily in the stomach, not the small intestine: it raises local gastric pH around the tablet, reducing pepsin activity and increasing the peptide's membrane permeability, allowing transcellular absorption through the gastric mucosa.^[4]

Enteric coatings and pH-sensitive release

Enteric coatings delay dissolution of a tablet or capsule until it reaches the higher pH of the proximal small intestine, bypassing gastric acid and pepsin. This protects acid- sensitive drugs but does not protect against intestinal proteases and does not solve the epithelial permeability problem. For peptides, enteric coatings alone are usually insufficient.

Protease inhibitors

Co-administering enzyme inhibitors such as camostat or aprotinin with a peptide can reduce intestinal proteolysis. This approach has been studied but has not reached broad clinical use, partly because systemic protease inhibition carries its own risks and partly because the epithelial permeability barrier remains even after proteolysis is suppressed.^[1]

Chemical modification

Modifications that reduce the peptide's susceptibility to proteolysis (D-amino acid substitutions, N-methylation, cyclization) improve stability in the gut but do not necessarily improve transepithelial permeability. Prodrug approaches (modifying the peptide to be inactive until absorbed, then cleaved to active form by tissue enzymes) are in research-stage development.^[6]

Worked example: oral semaglutide (Rybelsus)

Oral semaglutide (brand name Rybelsus) was approved by the FDA in 2019 for type 2 diabetes and represents the first orally bioavailable GLP-1 receptor agonist to reach the market. Its development illustrates both the potential of absorption-enhancer technology and its current limitations.

The SNAC mechanism was characterized in a 2018 Science Translational Medicine paper: SNAC creates a microenvironment of elevated pH immediately around the dissolving tablet, which reduces pepsin activity and renders the local gastric mucosa transiently more permeable to semaglutide. Absorption occurs in the stomach, not the small intestine.^[4]

The absolute bioavailability of oral semaglutide is approximately 1%, compared with approximately 89% for subcutaneous semaglutide.^[8]The 100-fold difference is the reason the oral doses (3 mg, 7 mg, 14 mg) are much higher than the subcutaneous doses (0.5 mg, 1 mg, 2 mg weekly). Both produce similar plasma exposures at their respective therapeutic doses.

In the PIONEER 4 trial, oral semaglutide 14 mg daily was non-inferior to subcutaneous semaglutide 1 mg weekly for HbA1c reduction (difference -0.1 percentage points, 95% CI -0.3 to 0.1), though with somewhat higher dropout due to GI adverse events.^[3]

The 1% bioavailability means that minor variation in gastric conditions has an outsized effect on exposure. Rybelsus must be taken on an empty stomach with no more than 120 mL of water, and the patient must wait 30 minutes before eating, drinking, or taking other medications. Food substantially reduces absorption. These requirements reflect the narrow conditions under which the SNAC mechanism works reliably.^[4],[5]

Summary

Bioavailability quantifies the fraction of a dose that reaches the systemic circulation. For peptides, the oral route is the most challenging because the gastrointestinal tract combines acid denaturation, protease digestion, and epithelial barrier function in a system designed to prevent exactly the kind of large-molecule absorption that a peptide drug requires.

Subcutaneous injection bypasses all three obstacles and achieves 50-89% bioavailability for most therapeutic peptides. Intranasal delivery avoids the gut and first-pass metabolism but is limited by nasal mucosal permeability to peptides below roughly 1,000 Da. Oral delivery remains a frontier: the SNAC-enabled absorption of semaglutide is the most successful example to date, achieving approximately 1% bioavailability with strict dosing conditions, which is sufficient to produce therapeutic plasma concentrations when dose is calibrated accordingly.